The role of gut hormones in glucose homeostasis

Journal of Clinical Investigation

Volumn 117, Issue 1, 2007, Pages 24-32

  Drucker, Daniel J ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CHOLECYSTOKININ; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GASTRIN; GASTROINTESTINAL HORMONE; GHRELIN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN GLARGINE; LIRAGLUTIDE; PROGLUCAGON; PROGLUCAGON DERIVED PEPTIDE; SITAGLIPTIN; SULFONYLUREA; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ABSORPTION; BODY WEIGHT; CLINICAL TRIAL; DIGESTION; DRUG MECHANISM; ENTERITIS; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TRACT; GLUCOSE HOMEOSTASIS; HUMAN; HYPOGLYCEMIA; INTESTINE INJURY; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET; PRIORITY JOURNAL; REVIEW; SATIETY; SIGNAL TRANSDUCTION; WEIGHT CONTROL;

ADENOSINE DEAMINASE; ANTIGENS, CD26; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; GLUCAGON; GLYCOPROTEINS; HOMEOSTASIS; HUMANS; INSULIN; PROGLUCAGON;

EID: 33845998516     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI30076     Document Type: Review

References (125)

1. Drucker, D.J. 2006. The biology of incretin hormones. Cell Metab. 3:153-165.
2. Drucker, D.J. 2003. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol. Endocrinol. 17:161-171.
3. Riddle, M.C., and Drucker, D.J. 2006. Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1. Diabetes Care. 29:435-449.
4. Dupre, J., Ross, S.A., Watson, D., and Brown, J.C. 1973. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J. Clin. Endocrinol. Metab. 37:826-828.
5. Pederson, R.A., Schubert, H.E., and Brown, J.C. 1975. Gastric inhibitory polypeptide. Its physiologic release and insulinotropic action in the dog. Diabetes. 24:1050-1056.
6. Usdin, T.B., Mezey, E., Button, D.C., Brownstein, M.J., and Bonner, T.I. 1993. Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology. 133:2861-2870.
7. Mayo, K.E., et al. 2003. International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol. Rev. 55:167-194.
8. Yip, R.G., Boylan, M.O., Kieffer, T.J., and Wolfe, M.M. 1998. Functional GIP receptors are present on adipocytes. Endocrinology. 139:4004-4007.
9. Mentlein, R., Gallwitz, B., and Schmidt, W.E. 1993. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem. 214:829-835.
10. Kieffer, T.J., McIntosh, C.H., and Pederson, R.A. 1995. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology. 136:3585-3596.
11. Deacon, C.F., Nauck, M.A., Meier, J., Hucking, K., and Holst, J.J. 2000. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J. Clin. Endocrinol. Metab. 85:3575-3581.
12. Gromada, J., et al. 1998. Glucagon-like peptide 1 (7-36) amide stimulates exocytosis in human pancreatic beta-cells by both proximal and distal regulatory steps in stimulus-secretion coupling. Diabetes. 47:57-65.
13. Trumper, A., et al. 2001. Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling. Mol. Endocrinol. 15:1559-1570.
14. Trumper, A., Trumper, K., and Horsch, D. 2002. Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells. J. Endocrinol. 174:233-246.
15. Kim, S.J., et al. 2005. GIP stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3-K)/protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1 and downregulation of bax expression. J. Biol. Chem. 280:22297-22307.
16. Tseng, C.C., Kieffer, T.J., Jarboe, L.A., Usdin, T.B., and Wolfe, M.M. 1996. Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat. J. Clin. Invest. 98:2440-2445.
17. Baggio, L., Kieffer, T.J., and Drucker, D.J. 2000. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, regulates fasting glycemia and nonenteral glucose clearance in mice. Endocrinology. 141:3703-3709.
18. Miyawaki, K., et al. 1999. Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc. Natl. Acad. Sci. U. S. A. 96:14843-14847.
19. Miyawaki, K., et al. 2002. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat. Med. 8:738-742.
20. Gault, V.A., et al. 2005. Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes. Diabetes. 54:2436-2446.
21. Nauck, M.A., et al. 1993. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J. Clin. Invest. 91:301-307.
22. Elahi, D., et al. 1994. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul. Pept. 51:63-74.
23. Fehmann, H.-C., Goke, R., and Goke, B. 1995. Cell and molecular biology of the incretin hormones glucagon-like peptide 1 and glucose-dependent releasing polypeptide. Endocr. Rev. 16:390-410.
24. Lynn, F.C., et al. 2001. Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. Diabetes. 50:1004-1011.
25. Meier, J.J., et al. 2004. Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects. Diabetes. 53(Suppl. 3):S220-S224.
26. Reimer, R.A., and McBurney, M.I. 1996. Dietary fiber modulates intestinal proglucagon messenger ribonucleic acid and postprandial secretion of glucagon-like peptide-1 and insulin in rats. Endocrinology. 137:3948-3956.
27. Tappenden, K.A., Thomson, A.B., Wild, G.E., and McBurney, M.I. 1996. Short-chain fatty acids increase proglucagon and ornithine decarboxylase messenger RNAs after intestinal resection in rats. JPEN J. Parenter. Enteral Nutr. 20:357-362.
28. Tappenden, K.A., and McBurney, M.I. 1998. Systemic short-chain fatty acids rapidly alter gastrointestinal structure, function, and expression of early response genes. Dig. Dis. Sci. 43:1526-1536.
29. Ulshen, M.H., et al. 1996. Increased ileal proglucagon expression after jejunectomy is not suppressed by inhibition of bowel growth. Dig. Dis. Sci. 41:677-683.
30. Taylor, R.G., Beveridge, D.J., and Fuller, P.J. 1992. Expression of ileal glucagon and peptide tyrosine-tyrosine genes. Response to inhibition of polyamine synthesis in the presence of massive small-bowel resection. Biochem. J. 286:737-741.
31. Brubaker, P.L., and Anini, Y. 2003. Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2. Can. J. Physiol. Pharmacol. 81:1005-1012.
32. Mojsov, S., Kopczynski, M.G., and Habener, J.F. 1990. Both amidated and nonamidated forms of glucagon-like peptide I are synthesized in the rat intestine and the pancreas. J. Biol. Chem. 265:8001-8008.
33. Orskov, C., Wettergren, A., and Holst, J.J. 1993. Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes. 42:658-661.
34. Wettergren, A., Pridal, L., Wojdemann, M., and Holst, J.J. 1998. Amidated and non-amidated glucagon-like peptide-1 (GLP-1): non-pancreatic effects (cephalic phase acid secretion) and stability in plasma in humans. Regul. Pept. 77:83-87.
35. Orskov, C., Rabenhoj, L., Wettergren, A., Kofod, H., and Holst, J.J. 1994. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes. 43:535-539.
36. Vilsboll, T., Krarup, T., Deacon, C.F., Madsbad, S., and Holst, J.J. 2001. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes. 50:609-613.
37. Hansen, L., Deacon, C.F., Orskov, C., and Holst, J.J. 1999. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology. 140:5356-5363.
38. Deacon, C.F., et al. 1995. Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes. 44:1126-1131.
39. Kreymann, B., Williams, G., Ghatei, M.A., and Bloom, S.R. 1987. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet. 2:1300-1304.
40. Mojsov, S., Weir, G.C., and Habener, J.F. 1987. Insulinotropin: glucagon-like peptide I (7-37) coencoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J. Clin. Invest. 79:616-619.
41. Orskov, C., Holst, J.J., and Nielsen, O.V. 1988. Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology. 123:2009-2013.
42. D'alessio, D.A., et al. 1996. Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons. J. Clin. Invest. 97:133-138.
43. Edwards, C.M., et al. 1999. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes. 48:86-93.
44. Wang, Z., et al. 1995. Glucagon-like peptide 1 is a physiological incretin in rat. J. Clin. Invest. 95:417-421.
45. Schirra, J., et al. 1998. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans. J. Clin. Invest. 101:1421-1430.
46. Scrocchi, L.A., et al. 1996. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide receptor gene. Nat. Med. 2:1254-1258.
47. Flamez, D., et al. 1998. Mouse pancreatic beta cells exhibit preserved glucose competence after disruption of the glucagon-like peptide 1 receptor gene. Diabetes. 47:646-652.
48. Wang, Y.H., et al. 1995. Glucagon-like peptide-1 affects gene transcription and messenger ribonucleic acid stability of components of the insulin secretory system in RIN 1046-38 cells. Endocrinology. 136:4910-4917.
49. Wang, Y., et al. 1997. Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats. J. Clin. Invest. 99:2883-2889.
50. Zander, M., Madsbad, S., Madsen, J.L., and Holst, J.J. 2002. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet. 359:824-830.
51. Degn, K.B., et al. 2004. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes. 53:1187-1194.
52. Fehse, F., et al. 2005. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J. Clin. Endocrinol. Metab. 90:5991-5997.
53. Xu, G., Stoffers, D.A., Habener, J.F., and Bonner-Weir, S. 1999. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes. 48:2270-2276.
54. Edvell, A., and Lindstrom, P. 1999. Initiation of increased pancreatic islet growth in young normoglycemic mice (Umea +/?). Endocrinology. 140:778-783.
55. Stoffers, D.A., et al. 2000. Insulinotropic glucagon-like peptide-1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes. 49:741-748.
56. Perfetti, R., Zhou, J., Doyle, M.E., and Egan, J.M. 2000. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology. 141:4600-4605.
57. Kim, J.G., et al. 2003. Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes. 52:751-759.
58. Ling, Z., et al. 2001. Glucagon-like peptide 1 receptor signaling influences topography of islet cells in mice. Virchows Arch. 438:382-387.
59. De Leon, D.D., et al. 2003. Role of endogenous glucagon-like peptide-1 in islet regeneration following partial pancreatectomy. Diabetes. 5252:365-371.
60. Li, Y., et al. 2003. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J. Biol. Chem. 278:471-478.
61. Buteau, J., et al. 2001. Protein kinase Czeta activation mediates glucagon-like peptide-1-induced pancreatic beta-cell proliferation. Diabetes. 50:2237-2243.
62. Brubaker, P.L., and Drucker, D.J. 2004. Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut and central nervous system. Endocrinology. 145:2653-2659.
63. Park, S., et al. 2005. Exendin-4 uses Irs2 signaling to mediate pancreatic beta cell growth and function. J. Biol. Chem. 281:1159-1168.
64. Buteau, J., Spatz, M.L., and Accili, D. 2006. Transcription factor FoxO1 mediates glucagon-like peptide-1 effects on pancreatic beta-cell mass. Diabetes. 55:1190-1196.
65. Farilla, L., et al. 2003. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology. 144:5149-5158.
66. Buteau, J., et al. 2004. Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia. 47:806-815.
67. Collie, N.L., Zhu, Z., Jordan, S., and Reeve, J.R., Jr. 1997. Oxyntomodulin stimulates intestinal glucose uptake in rats. Gastroenterology. 112:1961-1970.
68. Jarrousse, C., Bataille, D., and Jeanrenaud, B. 1984. A pure enteroglucagon, oxyntomodulin (glucagon 37), stimulates insulin release in perfused rat pancreas. Endocrinology. 115:102-105.
69. Wynne, K., et al. 2007. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int. J. Obes. (Lond.) In press.
70. Wynne, K., et al. 2005. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes. 54:2390-2395.
71. Dakin, C.L., et al. 2001. Oxyntomodulin inhibits food intake in the rat. Endocrinology. 142:4244-4250.
72. Baggio, L.L., Huang, Q., Brown, T.J., and Drucker, D.J. 2004. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology. 127:546-558.
73. Cheeseman, C.I., and Tsang, R. 1996. The effect of gastric inhibitory polypeptide and glucagon like peptides on intestinal hexose transport. Am. J. Physiol. Gastrointest. Liver Physiol. 271:G477-G482.
74. Boushey, R.P., Yusta, B., and Drucker, D.J. 1999. Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. Am. J. Physiol. 277:E937-E947.
75. Boushey, R.P., Yusta, B., and Drucker, D.J. 2001. Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor. Cancer Res. 61:687-693.
76. Jeppesen, P.B., et al. 2001. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology. 120:806-815.
77. Jeppesen, P.B. 2003. Clinical significance of GLP-2 in short-bowel syndrome. J. Nutr. 133:3721-3724.
78. Jeppesen, P.B., et al. 2005. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut. 54:1224-1231.
79. Meier, J.J., et al. 2006. Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. Gastroenterology. 130:44-54.
80. Gutniak, M., Orskov, C., Holst, J.J., Ahren, B., and Efendic, S. 1992. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N. Engl. J. Med. 326:1316-1322.
81. Rachman, J., et al. 1996. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1(7-36)amide in patients with NIDDM. Diabetes. 45:1524-1530.
82. Rachman, J., Barrow, B.A., Levy, J.C., and Turner, R.C. 1997. Near normalization of diurnal glucose concentrations by continuous administration of glucagon-like peptide 1 (GLP-1) in subjects with NIDDM. Diabetologia. 40:205-211.
83. Todd, J.F., Wilding, J.P., Edwards, C.M., Ghatei, M.A., and Bloom, S.R. 1997. Glucagon-like peptide-1 (GLP-1): a trial of treatment in non-insulin-dependent diabetes mellitus. Eur. J. Clin. Invest. 27:533-536.
84. Eng, J., Kleinman, W.A., Singh, L., Singh, G., and Raufman, J.P. 1992. Isolation and characterization of exendin 4, an exendin 3 analogue from Heloderma suspectum venom. J. Biol. Chem. 267:7402-7405.
85. Goke, R., et al. 1993. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)amide receptor of insulin-secreting β-cells. J. Biol. Chem. 268:19650-19655.
86. Chen, Y.E., and Drucker, D.J. 1997. Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard. J. Biol. Chem. 272:4108-4115.
87. Buse, J.B., et al. 2004. Effects of exenatide (Exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 27:2628-2635.
88. DeFronzo, R.A., et al. 2005. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 28:1092-1100.
89. Kendall, D.M., et al. 2005. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 28:1083-1091.
90. Heine, R.J., et al. 2005. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann. Intern. Med. 143:559-569.
91. Harder, H., Nielsen, L., Tu, D.T., and Astrup, A. 2004. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care. 27:1915-1921.
92. Madsbad, S., Schmitz, O., Ranstam, J., Jakobsen, G., and Matthews, D.R. 2004. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care. 27:1335-1342.
93. Gedulin, B.R., et al. 2005. Dose-response for glycaemic and metabolic changes 28 days after single injection of long-acting release exenatide in diabetic fatty Zucker rats. Diabetologia. 48:1380-1385.
94. Mitani, H., Takimoto, M., Hughes, T.E., and Kimura, M. 2002. Dipeptidyl peptidase IV inhibition improves impaired glucose tolerance in high-fat diet-fed rats: study using a Fischer 344 rat substrain deficient in its enzyme activity. Jpn. J. Pharmacol. 88:442-450.
95. Marguet, D., et al. 2000. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc. Natl. Acad. Sci. U. S. A. 97:6874-6879.
96. Ahren, B., Holst, J.J., Martensson, H., and Balkan, B. 2000. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. Eur. J. Pharmacol. 404:239-245.
97. Pederson, R.A., et al. 1998. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes. 47:1253-1258.
98. Ahren, B., et al. 2004. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J. Clin. Endocrinol. Metab. 89:2078-2084.
99. Ahren, B., et al. 2002. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care. 25:869-875.
100. Ahren, B., Holst, J.J., and Efendic, S. 2000. Anti-diabetogenic action of cholecystokinin-8 in type 2 diabetes. J. Clin. Endocrinol. Metab. 85:1043-1048.
101. Boushey, R.P., et al. 2003. Hypoglycemia, defective islet glucagon secretion, but normal islet mass in mice with a disruption of the gastrin gene. Gastroenterology. 125:1164-1174.
102. Kuntz, E., Pinget, M., and Damge, P. 2004. Cholecystokinin octapeptide: a potential growth factor for pancreatic beta cells in diabetic rats. JOP. 5:464-475.
103. Rooman, I., Lardon, J., and Bouwens, L. 2002. Gastrin stimulates beta-cell neogenesis and increases islet mass from transdifferentiated but not from normal exocrine pancreas tissue. Diabetes. 51:686-690.
104. Rooman, I., and Bouwens, L. 2004. Combined gastrin and epidermal growth factor treatment induces islet regeneration and restores normoglycaemia in C57Bl6/J mice treated with alloxan. Diabetologia. 47:259-265.
105. Suarez-Pinzon, W.L., Yan, Y., Power, R., Brand, S.J., and Rabinovitch, A. 2005. Combination therapy with epidermal growth factor and gastrin increases beta-cell mass and reverses hyperglycemia in diabetic NOD mice. Diabetes. 54:2596-2601.
106. Suarez-Pinzon, W.L., Lakey, J.R., Brand, S.J., and Rabinovitch, A. 2005. Combination therapy with epidermal growth factor and gastrin induces neogenesis of human islet beta-cells from pancreatic duct cells and an increase in functional beta-cell mass. J. Clin. Endocrinol. Metab. 90:3401-3409.
107. Druce, M.R., et al. 2005. Ghrelin increases food intake in obese as well as lean subjects. Int. J. Obes. (Lond.) 29:1130-1136.
108. Prado, C.L., Pugh-Bernard, A.E., Elghazi, L., Sosa-Pineda, B., and Sussel, L. 2004. Ghrelin cells replace insulin-producing beta cells in two mouse models of pancreas development. Proc. Natl. Acad. Sci. U. S. A. 101:2924-2929.
109. Dezaki, K., et al. 2004. Endogenous ghrelin in pancreatic islets restricts insulin release by attenuating Ca2+ signaling in beta-cells: implication in the glycemic control in rodents. Diabetes. 53:3142-3151.
110. Sun, Y., Asnicar, M., Saha, P.K., Chan, L., and Smith, R.G. 2006. Ablation of ghrelin improves the diabetic but not obese phenotype of ob/ob mice. Cell Metab. 3:379-386.
111. Theander-Carrillo, C., et al. 2006. Ghrelin action in the brain controls adipocyte metabolism. J. Clin. Invest. 116:1983-1993. doi:10.1172/JCI25811.
112. Irako, T., et al. 2006. Ghrelin prevents development of diabetes at adult age in streptozotocin-treated newborn rats. Diabetologia. 49:1264-1273.
113. Besterman, H.S., et al. 1982. Gut hormone release after intestinal resection. Gut. 23:854-861.
114. Besterman, H.S., et al. 1983. Gut hormones in inflammatory bowel disease. Scand. J. Gastroenterol. 18:845-852.
115. Xiao, Q., Boushey, R.P., Cino, M., Drucker, D.J., and Brubaker, P.L. 2000. Circulating levels of glucagon-like peptide-2 in human subjects with inflammatory bowel disease. Am. J. Physiol. 278:R1057-R1063.
116. Naslund, E., Backman, L., Holst, J.J., Theodorsson, E., and Hellstrom, P.M. 1998. Importance of small bowel peptides for the improved glucose metabolism 20 years after jejunoileal bypass for obesity. Obes. Surg. 8:253-260.
117. Le Roux, C.W., et al. 2006. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann. Surg. 243:108-114.
118. Morinigo, R., et al. 2006. Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. J. Clin. Endocrinol. Metab. 91:1735-1740.
119. Patti, M.E., et al. 2005. Severe hypoglycemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia. Diabetologia. 4:2236-2240.
120. Service, G.J., et al. 2005. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N. Engl. J. Med. 353:249-254.
121. Meier, J.J., Butler, A.E., Galasso, R., and Butler, P.C. 2006. Hyperinsulinemic hypoglycemia after gastric bypass surgery is not accompanied by islet hyperplasia or increased beta-cell turnover. Diabetes Care. 29:1554-1559.
122. Jackson, R.S., et al. 2003. Small-intestinal dysfunction accompanies the complex endocrinopathy of human proprotein convertase 1 deficiency. J. Clin. Invest. 112:1550-1560. doi:10.1172/JCI200318784.
123. Wang, J., et al. 2006. Mutant neurogenin-3 in congenital malabsorptive diarrhea. N. Engl. J. Med. 355:270-280.
124. Grant, S.F., et al. 2006. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat. Genet. 38:320-323.
125. Florez, J.C., et al. 2006. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N. Engl. J. Med. 355:241-250.